Gå til indhold
FORSIDEN | LÆS OP | REN TEKST | PRINT | SITEMAP |
Header

Karina Dahl Steffensen

Karina Dahl Steffensen   

Professor
Overlæge, MD., Ph.d. Karina Dahl Steffensen
Onkologisk afdeling, Vejle Sygehus

Center for Fælles Beslutningstagning
Patienternes Kræftsygehus - en del af Sygehus Lillebælt
http://www.cffb.dk/

 

E-mail: Karina.Dahl.Steffensen@rsyd.dk

 

Uddannelse


  • Doctor of Medicine, MD. University of Aarhus, Denmark, 1999
  • Certificate and Authorization as a Physician. National Board of Health, Copenhagen, Denmark, 1999
  • Certificate and permission to Practice Independently as a Physician, National Board of Health, Copenhagen, 2000
  • PhD degree, University of Southern Denmark, 2008
  • Certification as a medical specialist in Clinical Oncology (medical and radiotherapy). National Board of Health, Copenhagen, 2014
  • Professor, Institut for Regional Sundhedsforskning, SDU, 2018-

 

Ansvarsområder


  • Director, Center for Shared Decision Making, Lillebaelt Hospital–Vejle
  • Associate Professor (lecturer), Institute of Regional Health Sciences, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
  • Consultant (Overlæge) Medical Oncology, Department of Oncology and Radiotherapy, Vejle Hospital, Denmark

 

Nuværende projekter og udviklingsaktiviteter


  • Development, evaluation & effectiveness of a decision aid for patients choosing surgical or non-surgical treatment for lumbar herniated disc
  • Pulmonary abnormalities of uncertain significance: Shared decision making on diagnostic work-up
  • Development of a new decision aid for women with early breast cancer
  • Individual survivorship program for ovarian cancer patients based on PROMs and shared decision making
  • Optimization of follow-up for postmenopausal breast cancer patients undergoing adjuvant endocrine therapy
  • The clinical importance of BRCAness in a Danish cohort of epithelial ovarian carcinoma”.
  • Sponsor (IST protocol): Natural killer cells activity, neutrophils, and circulating tumor cells in recurrent ovarian cancer patients treated with chemotherapy
  • Sponsor (IST protocol): Natural killer cells activity, neutrophils, and circulating tumor cells in ovarian cancer patients treated with neoadjuvant chemotherapy
     

Afsluttede projekter


  • Co-investigator (IST biomarker trial): Molecular biological markers in tissue and blood during neoadjuvant treatment for breast cancer
  • Principal investigator (IST biomarker trial): Molecular biological markers in tissue and blood in epithelial ovarian cancer in first line combination treatment with Carboplatin and Taxol
  • Principal investigator (IST biomarker trial): Molecular biological markers in ovarian cancer
  • Principal investigator (IST biomarker trial): Prognostic significance of HER2 and other molecular biological factors in epithelial ovarian cancer
  • Principal investigator (IST protocol): Veliparib (ABT888) Monotherapy to Patients with BRCA germ line mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer
  • Principal investigator: PaLiDo Protocol (IST phase II trial), Panitumumab (Vectibix®) and Pegylated Liposomal Doxorubicin (Caelyx®) to Platinum-Resistant Epithelial Ovarian Cancer with KRAS Wild-type

 

Udvalg


  • Member Center for User Involvement in Health Care(ViBIS) “think tank”: Expert group for researchers
  • Faculty member - European Society of Medical Oncology (ESMO)  – Gynecological Cancer
  • Member of international network of researchers in shared decision making (4 annual web meetings)
  • Committee member - Danish National Comprehensive Cancer Centre (DCCC)
  • European Society of Medical Oncology (ESMO) – ESMO Faculty member – Gynecological Cancer
  • Member International steering committee: Clinical Study Protocol M13-694 (a phase 3 clinical randomized study with a first line PARP inhibitor)
  • Appointed member (for Region SouthDenmark) – national clinical coordination group - RSI Landmark (Regions Health IT): Patient Reported Outcomes (PRO) for Priority of Outpatient Controls on Epilepsy, Prostate Cancer and Chemotherapy in Breast Cancer
  • Committee member – Danish Gynaecological Cancer Group (DGCG)
  • Committee member – Danish Gynaecological Cancer Screening Group (DGCG)
  • DGCG’s Research Group (deputy chairman)

 

Publikationer og aktiviteter


Se link til Karina Dahl Steffensen's publikationer, aktiviteter m.m. på SDU - link

 


Siden er sidst opdateret 02-05-2018.
Kontakt: admtda



Sygehus Lillebælt | Telefon 76 36 20 00 | Send sikker e-mail til Sygehus Lillebælt